NASDAQ: AKTX
Akari Therapeutics PLC Stock

$1.12-0.12 (-9.68%)
Updated Feb 10, 2025
AKTX Price
$1.12
Fair Value Price
$0.79
Market Cap
$55.46M
52 Week Low
$0.90
52 Week High
$4.40
P/E
N/A
P/B
-8.28x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.41
Operating Cash Flow
N/A
Beta
0.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

AKTX Overview

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine AKTX's potential to beat the market

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
AKTX
Ranked
Unranked of 557

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important AKTX news, forecast changes, insider trades & much more!

AKTX News

Overview

Due Diligence Score

–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AKTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AKTX ($1.12) is overvalued by 42.57% relative to our estimate of its Fair Value price of $0.79 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AKTX ($1.12) is not significantly undervalued (42.57%) relative to our estimate of its Fair Value price of $0.79 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AKTX's short-term liabilities ($9.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more AKTX due diligence checks available for Premium users.

Valuation

AKTX fair value

Fair Value of AKTX stock based on Discounted Cash Flow (DCF)

Price
$1.12
Fair Value
$0.79
Overvalued by
42.57%
AKTX ($1.12) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AKTX ($1.12) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

AKTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-8.28x
Industry
4.86x

AKTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$2.9M
Profit Margin
0%

Assets to liabilities

Assets
$2.7M
Liabilities
$9.4M
Debt to equity
-1.41
AKTX's short-term liabilities ($9.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKTX's short-term assets ($2.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AKTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.5M
Investing
$0.0
Financing
-$443.0k

AKTX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
AKTX–$55.46M-9.68%N/A-8.28x
UNCYD$56.05M-4.59%-0.73x2.01x
ALXOD$54.85M-4.59%-0.35x0.40x
LTRND$54.46M-0.39%-2.84x2.05x
PDSBD$54.24M-0.68%-1.24x2.47x

Akari Therapeutics Stock FAQ

What is Akari Therapeutics's quote symbol?

(NASDAQ: AKTX) Akari Therapeutics trades on the NASDAQ under the ticker symbol AKTX. Akari Therapeutics stock quotes can also be displayed as NASDAQ: AKTX.

If you're new to stock investing, here's how to buy Akari Therapeutics stock.

What is the 52 week high and low for Akari Therapeutics (NASDAQ: AKTX)?

(NASDAQ: AKTX) Akari Therapeutics's 52-week high was $4.40, and its 52-week low was $0.90. It is currently -74.55% from its 52-week high and 24.44% from its 52-week low.

How much is Akari Therapeutics stock worth today?

(NASDAQ: AKTX) Akari Therapeutics currently has 49,517,115,523 outstanding shares. With Akari Therapeutics stock trading at $1.12 per share, the total value of Akari Therapeutics stock (market capitalization) is $55.46M.

Akari Therapeutics stock was originally listed at a price of $1,600.00 in Jan 6, 2014. If you had invested in Akari Therapeutics stock at $1,600.00, your return over the last 11 years would have been -99.93%, for an annualized return of -48.34% (not including any dividends or dividend reinvestments).

How much is Akari Therapeutics's stock price per share?

(NASDAQ: AKTX) Akari Therapeutics stock price per share is $1.12 today (as of Feb 10, 2025).

What is Akari Therapeutics's Market Cap?

(NASDAQ: AKTX) Akari Therapeutics's market cap is $55.46M, as of Feb 11, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Akari Therapeutics's market cap is calculated by multiplying AKTX's current stock price of $1.12 by AKTX's total outstanding shares of 49,517,115,523.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.